Correction: CXCL13 suppresses liver regeneration through the negative regulation of HGF signaling by Qun Zhao, Jingyi Wu, Mengyuan Feng, Anjie Zhang, Liwei Fu, Jinglin Chen, Lian Li, Fangzhou Li, Tingting Li, Shu Jin, Shengbao Li, Xianjun Yu

Get full text

CXCL13 suppresses liver regeneration through the negative regulation of HGF signaling by Qun Zhao, Jingyi Wu, Mengyuan Feng, Anjie Zhang, Liwei Fu, Jinglin Chen, Lian Li, Fangzhou Li, Tingting Li, Shu Jin, Shengbao Li, Xianjun Yu

Get full text

Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population‐based study by Panpan Zhang, Wei Wang, Ming Lu, Changqing Zeng, Jie Chen, Enxiao Li, Huangying Tan, Wei Wang, Xianjun Yu, Qiyun Tang, Jiemin Zhao, Lin Shen, Jie Li

Get full text

Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma by Miaoyan Wei, Rujiao Liu, Yunyun Xu, Xiaobing Chen, Chao Liu, Xueli Bai, Xiaochen Zhang, Shuiping Gao, Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang, Jian Zhang, Si Shi, Jin Xu, Xianjun Yu

Get full text

Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma by Miaoyan Wei, Rujiao Liu, Yunyun Xu, Xiaobing Chen, Chao Liu, Xueli Bai, Xiaochen Zhang, Shuiping Gao, Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang, Jian Zhang, Si Shi, Jin Xu, Xianjun Yu

Get full text